The latest call
FetchingAltimmune, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Loading company
Altimmune, Inc.
ALT · Nasdaq · ·
$1.64+2.2%Nov 13 close
The latest quarter (ended September 30, 2026) is from Altimmune’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once Altimmune files it.
Past performance
- 1W
- -21.2%
- 1M
- -29.0%
What Altimmune, Inc. reported on November 12, 2026
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $26K | $5K | +420.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
What management said
“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$1.93
Nov 11, 2026
Close after
$1.64
Nov 13, 2026
Move
-15.03%
0 shares traded, against a normal 3.3M
What Altimmune, Inc. does
Pemvidutide is a novel, investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that has an effect on reducing liver fat, inflammation, and fibrosis, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss and are involved in pathways related to craving and reward. The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH, was initiated. In July 2026, the Company announced positive topline results from the RECLAIM Phase 2 trial in AUD. In August 2026, the Company announced completion of enrollment of the RESTORE Phase 2 trial in ALD.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Altimmune’s earnings press release (an Item 2.02 8-K) filed November 12, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.